Newsroom | 36321 results

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2025 (nine months ended December 31, 2025). The gap between incremental Growth & Launch Products revenue and VYVANSE erosion is narrowing, and operational efficiencies drove year-on-year reductions in operating expenses, including R&D. The company raised its full-year forecasts based on cost discipline and FX tailwind, while its Revenue Management Guidance ha...

比利時根特、賓夕法尼亞州瑪律文和東京--(BUSINESS WIRE)--(美國商業資訊)-- H.U. Group Holdings Inc.及其獨資子公司Fujirebio今日宣布推出適用於全自動LUMIPULSE® G免疫分析系統的Lumipulse G pTau 217腦脊液檢測試劑。該化學發光酶免疫分析(CLEIA)試劑僅限研究用途(RUO)，可在短短35分鐘內對人腦脊液(CSF)中的蘇胺酸217位點磷酸化Tau蛋白(pTau 217)進行量化檢測。 阿茲海默症(AD)的特徵是大腦中神經原纖維纏結和類澱粉斑塊的累積，前者由過度磷酸化的Tau蛋白構成，後者由特定的β-類澱粉胜肽組成。腦脊液pTau217已成為與阿茲海默症相關神經病理變化的早期生物標記。 這款新型免疫檢測試劑進一步豐富了Fujirebio不斷壯大的神經生物標記產品組合，同時鞏固了公司在相關研究工具和診斷技術發展方面的領先地位。 Fujirebio Holdings, Inc.總裁兼執行長Goki Ishikawa表示：「將pTau 217腦脊液檢測試劑納入我們的神經產品組合後，臨床研究人員能夠更深入地探究其在疾病...

比利时根特、宾夕法尼亚州马尔文和东京--(BUSINESS WIRE)--(美国商业资讯)-- H.U. Group Holdings Inc.及其全资子公司Fujirebio今日宣布推出适用于全自动LUMIPULSE® G免疫分析系统的Lumipulse G pTau 217脑脊液检测试剂。该化学发光酶免疫分析(CLEIA)试剂仅限研究用途(RUO)，可在短短35分钟内对人脑脊液(CSF)中的苏氨酸217位点磷酸化Tau蛋白(pTau 217)进行定量检测。 阿尔茨海默病(AD)的特征是大脑中神经原纤维缠结和淀粉样斑块的积累，前者由过度磷酸化的Tau蛋白构成，后者由特定的β-淀粉样肽组成。脑脊液pTau217已成为与阿尔茨海默病相关神经病理变化的早期生物标志物。 这款新型免疫检测试剂进一步丰富了Fujirebio不断壮大的神经生物标志物产品组合，同时巩固了公司在相关研究工具和诊断技术发展方面的领先地位。 Fujirebio Holdings, Inc.总裁兼首席执行官Goki Ishikawa表示：“将pTau 217脑脊液检测试剂纳入我们的神经产品组合后，临床研究人员能够更深入地探...

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) announced today the completion of the previously announced acquisition of all of the issued and outstanding common shares of the Company (the “Common Shares” and the holders of the Common Shares, the “Shareholders”) by XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly “Xeno”) a non-profit biotechnology company, by way of a statutory plan of arrangement (the “Transaction” or the “Arrangeme...

GENT, Bélgica, MALVERN, Pensilvânia e TÓQUIO--(BUSINESS WIRE)--A H.U. Group Holdings Inc. e sua subsidiária integral Fujirebio anunciaram hoje a disponibilidade do ensaio Lumipulse G pTau 217 CSF para os analisadores imunoquímicos totalmente automatizados LUMIPULSE® G. Este ensaio CLEIA (imunoensaio enzimático quimioluminescente) está disponível apenas para uso em pesquisa (RUO) e permite a medição quantitativa da proteína Tau fosforilada na treonina 217 (pTau 217) no líquido cefalorraquidiano...

GENT, Belgique et MALVERN, Pennsylvanie et TOKYO--(BUSINESS WIRE)--H.U. Group Holdings Inc. et sa filiale en propriété exclusive Fujirebio ont annoncé aujourd’hui la mise sur le marché du test Lumipulse G pTau 217 CSF pour les analyseurs immunologiques entièrement automatisés LUMIPULSE® G. Ce test CLEIA (test immunoenzymatique chimiluminescent) est disponible à des fins de recherche uniquement (RUO) et permet la mesure quantitative de la protéine Tau phosphorylée en thréonine 217 (pTau 217) dan...

GENT, Bélgica; MALVERN (Pensilvania) y TOKIO--(BUSINESS WIRE)--H.U. Group Holdings Inc. y su filial de propiedad exclusiva Fujirebio anunciaron hoy la disponibilidad del ensayo Lumipulse G pTau 217 CSF para los analizadores de inmunoensayos totalmente automatizados LUMIPULSE® G. Este ensayo CLEIA (ensayo inmunoenzimático por quimioluminiscencia) está disponible solo para uso en investigación (Research Use Only, RUO) y permite la medición cuantitativa de la proteína Tau fosforilada en treonina 2...

GENT, Belgien & MALVERN, Pennsylvania & TOKIO--(BUSINESS WIRE)--Die H.U. Group Holdings Inc. und ihre hundertprozentige Tochtergesellschaft Fujirebio gaben heute die Verfügbarkeit des Lumipulse G pTau 217 CSF-Assays für die vollautomatischen LUMIPULSE® G-Immunoassay-Analysegeräte bekannt. Dieser CLEIA-Assay (Chemilumineszenz-Enzymimmunoassay) ist nur für Forschungszwecke (RUO) erhältlich und ermöglicht die quantitative Messung von Tau, phosphoryliert an Threonin 217 (pTau 217), im menschlichen...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 at the Cliff Lodge in Snowbird, UT. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new par...

GENT, België & MALVERN, Pa. & TOKIO--(BUSINESS WIRE)--Vandaag hebben H.U. Group Holdings Inc. en zijn volledige dochteronderneming Fujirebio bekendgemaakt dat de Lumipulse G pTau 217 CSF-test beschikbaar is voor de volledig geautomatiseerde LUMIPULSE® G-immunoassay-analysers. De CLEIA-test (chemiluminescentie-enzymimmunoassay) is uitsluitend beschikbaar voor onderzoeksdoeleinden (RUO). Deze maakt binnen slechts 35 minuten een kwantitatieve meting mogelijk van Tau gefosforyleerd op threonine 217...